Gastrointestinal Stromal Tumor

Oncology
7
Pipeline Programs
6
Companies
23
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
3
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Monoclonal Antibody
150%
+ 5 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
SUTENTApproved
sunitinib malate
Unknown Company
oral2006

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
sunitinib malatePhase 31 trial
Active Trials
NCT00372567Terminated69Est. Nov 2009
Novartis
NovartisBASEL, Switzerland
2 programs
1
AUY922Phase 25 trials
GlivecN/A1 trial
Active Trials
NCT01613053No Longer Available
NCT02276027Completed66Est. Oct 2019
NCT01784640Completed13Est. Oct 2018
+3 more trials
Bristol Myers Squibb
1 program
1
IpilimumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT02880020Completed36Est. Aug 2022
Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
rubitecanPhase 21 trial
Active Trials
NCT00005874CompletedEst. Apr 2004
Mendus
MendusSweden - Stockholm
1 program
1
IntuvaxPhase 11 trial
Active Trials
NCT02686944CompletedEst. May 2019
Bayer
BayerLEVERKUSEN, Germany
1 program
1
SunitinibPhase 1Small Molecule

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pfizersunitinib malate
Bristol Myers SquibbIpilimumab
NovartisAUY922
NovartisAUY922
NovartisAUY922
NovartisAUY922
NovartisAUY922
NovartisAUY922
NovartisAUY922
NovartisAUY922
NovartisAUY922
Astex Pharmaceuticalsrubitecan
NovartisAUY922
NovartisAUY922
NovartisAUY922

Showing 15 of 22 trials with date data

Clinical Trials (23)

Total enrollment: 864 patients across 23 trials

NCT00372567Pfizersunitinib malate

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

Start: Jun 2007Est. completion: Nov 200969 patients
Phase 3Terminated
NCT02880020Bristol Myers SquibbIpilimumab

Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery

Start: Dec 2016Est. completion: Aug 202236 patients
Phase 2Completed
NCT02276027NovartisAUY922

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

Start: Jan 2015Est. completion: Oct 201966 patients
Phase 2Completed
NCT01646125NovartisAUY922

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Start: Nov 2012Est. completion: Nov 201559 patients
Phase 2Terminated
NCT01668173NovartisAUY922

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Start: Aug 2012Est. completion: May 20157 patients
Phase 2Terminated
NCT01485536NovartisAUY922

A Study of the HSP90 Inhibitor AUY922

Start: Aug 2012Est. completion: Nov 201521 patients
Phase 2Terminated
NCT01484860NovartisAUY922

Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy

Start: Jan 2012Est. completion: Aug 201315 patients
Phase 2Terminated
NCT01404650NovartisAUY922

Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor

Start: Dec 2011Est. completion: Feb 201525 patients
Phase 2Completed
NCT01402401NovartisAUY922

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

Start: Nov 2011Est. completion: Jun 201321 patients
Phase 2Terminated
NCT01124864NovartisAUY922

A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

Start: Oct 2010Est. completion: Aug 2014153 patients
Phase 2Completed
NCT01084330NovartisAUY922

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Start: Apr 2010Est. completion: May 201268 patients
Phase 2Completed
NCT00005874Astex Pharmaceuticalsrubitecan

Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas

Start: Jun 1999Est. completion: Apr 2004
Phase 2Completed
NCT01271920NovartisAUY922

Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Start: Sep 2010Est. completion: Oct 201345 patients
Phase 1/2Completed
NCT00708292NovartisAUY922

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Start: Jul 2008Est. completion: Jan 201129 patients
Phase 1/2Completed
NCT00526045NovartisAUY922

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Start: Jul 2007Est. completion: Apr 2012117 patients
Phase 1/2Completed
NCT02686944MendusIntuvax

A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors

Start: Jun 2016Est. completion: May 2019
Phase 1Completed
NCT01784640NovartisAUY922

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

Start: Jan 2014Est. completion: Oct 201813 patients
Phase 1Completed
NCT01772797NovartisAUY922

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

Start: Jun 2013Est. completion: Jan 201622 patients
Phase 1Completed
NCT01613950NovartisAUY922

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Start: Dec 2012Est. completion: Mar 201418 patients
Phase 1Completed
NCT01294826NovartisAUY922

Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Start: Feb 2011Est. completion: May 201520 patients
Phase 1Completed
NCT01226732NovartisAUY922

A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

Start: Nov 2010Est. completion: Jun 201423 patients
Phase 1Completed
NCT01132625NovartisAUY922

Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan

Start: Nov 2008Est. completion: May 201237 patients
Phase 1Completed
NCT01613053NovartisGlivec

Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination

N/ANo Longer Available

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)